Hisamitsu Pharmaceutical Co., Inc.
HTSUY · OTC
11/30/2025 | 8/31/2025 | 5/31/2025 | 2/28/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.19 | -0.42 | 0.15 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 23.37 | 28.43 | 33.72 | 17.22 |
| Quality | ||||
| ROIC | 1.25% | 1.23% | 0.80% | 1.66% |
| Gross Margin | 58.48% | 61.59% | 61.40% | 55.43% |
| Cash Conversion Ratio | 1.00 | 1.00 | 1.00 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -69.25% | 2.08% | 245.26% | 248.34% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -11.88 | -7.19 | -18.71 | -10.18 |
| Interest Coverage | 896.20 | 595.38 | 1,683.09 | 709.39 |
| Efficiency | ||||
| Inventory Turnover | 0.66 | 0.62 | 0.53 | 0.87 |
| Cash Conversion Cycle | 152.32 | 154.97 | 187.24 | 134.52 |